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Plakortin (1) is a remarkably simple 1,2-dioxane derivative, extracted from the marine sponge Plakortis
simplex, showing a submicromolar activity against chloroquine-resistant strains of Plasmodium falciparum.
Using plakortin as a novel antimalarial hit, we have prepared a series of semisynthetic derivatives in order
to gain insights into the structural requirements of simple 1,2-dioxanes for exhibiting antimalarial activity.
Their synthesis, spectroscopic and computational analysis, and in vitro antimalarial activity are herein reported.
Results obtained, besides confirming the crucial role of the cycloperoxide functionality, revealed other
structural features critical for antimalarial activity, namely the “Western” alkyl side chain, the dioxane ring
conformation, and the absolute configuration of the stereogenic carbons on the 1,2-dioxane ring, when affecting
the bioactive ring conformation.
Introduction
Malaria, a parasitic disease caused by protozoans belonging
to the genus Plasmodium, is recognized as one of the most
dramatic public health concerns of our days. Indeed, it occurs
in over 90 countries worldwide and, according to valuations
provided by the World Health Organization, 300 to 500 million
clinical cases of malaria occur and 1.5-2 million people (most
of them young children living in sub-Saharan Africa) are killed
each year.1 The difficulties associated with the preparation of
an effective vaccine against malaria can be ascribed to the
complexity of this disease, that varies widely in epidemiology
(variability in the species of malaria parasite that occur in a
given area) and clinical manifestations in different parts of the
world. However, the development and spread of drug-resistant
strains of malaria parasites is probably the key factor in the
resurgence of malaria emergency, also in areas where the disease
had been eradicated, and is one of the greatest challenges to
malaria control today.2 Unfortunately, the rate at which resist-
ance is growing outpaces the development of new antimalarials
and, thus, the number of effective drugs available to treat
resistant malaria remains small.
Artemisinin, a cycloperoxide-containing sesquiterpene lactone
extracted from the plant Artemisia annua, shows higher activity
against chloroquine-resistant strains (CQ-R) than chloroquine-
sensitive strains (CQ-S) of P. falciparum. Accordingly, a series
of artemisinin semisynthetic derivatives (artesunate, artemether,
arteether), with improved pharmacokinetic properties, have been
proposed for the treatment of severe malaria and, in some areas
of South-East Asia, their combination with mefloquine offer
the only reliable treatment for multidrug-resistant malaria.3
However, also in the case of artemisinin-derived molecules some
problems are appearing. These are mostly related to (i) some
adverse effects (neurological and embriological) caused by their
use,4 (ii) the costs associated with the extraction of artemisinin
from natural sources and the complexity of alternative chemical
syntheses.5
For these reasons, there is an urgent need for the rapid
development of effective, safe, and synthetically affordable
antimalarial agents. In this regard, we have been focusing our
interest on 1,2-dioxane derivatives isolated from the Caribbean
sponge Plakortis simplex possessing remarkably simple skel-
etons: the parent compounds of this class, plakortin (1) and its
9,10-dihydro analogue 2, have been demonstrated to possess
in vitro antimalarial activity in the submicromolar range, being
particularly active on CQ-R strains (IC50 ) 0.41 íM), and
devoid of general cytotoxicity.6,7 More recently, we have isolated
two additional analogues of plakortin from the same sponge,
namely 3-epiplakortin (3) and plakortide Q (4) (Figure 1).8 These
analogues showed in vitro antimalarial activity similar to that
of plakortin (IC50 ) 0.51 íM), suggesting that the activity of
this class of compounds is not strictly dependent on a definite
configuration of the stereogenic carbons belonging to the 1,2-
dioxane ring. Due to the tremendous need to develop new classes
of affordable, rapidly acting drugs to treat uncomplicated
malaria, exploiting the natural compound plakortin (1) as a novel
antimalarial hit, we herein report the synthesis, the spectroscopic
and computational analysis, and the in vitro antimalarial activity
of a series of plakortin semisynthetic derivatives.
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Figure 1. 1,2-Dioxane derivatives isolated from the sponge Plakortis
simplex.
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Chemistry. Plakortin (1) can be isolated in high amounts
(more than 5% of the organic extract) from Plakortis simplex,
following a very simple procedure, and it is stable under
extraction and chromatographic purification steps.6 The avail-
ability of reasonable amounts of 1, its stability, and the presence
in its monocyclic skeleton of functional groups that could be
modified, appeared a good opportunity to investigate the effect
of chemical transformations on antimalarial activity, allowing
an extension of the structure-activity relationships (SARs) for
this class of antimalarial endoperoxides.
The simple structure of plakortin offers three points for
chemical interconversion: (i) the cycloperoxide bond, (ii) the
carbon-carbon double bond, (iii) the ester group. These
functionalities have been subjected to simple chemical reactions
and the products obtained (5-12) have been fully characterized
by means of MS and 1D and 2D NMR spectroscopy (data are
listed in the Experimental Section).
A selective reduction of the cycloperoxide bond was ac-
complished upon treatment of plakortin (1) with acetic acid and
Zn dust in dry ether, affording the diol 5 in good yield (Scheme
1). As for the ester group, its selective reduction, without
affecting the cycloperoxide bond, was carried out by treating 1
with LiBH4 in dry THF, thus obtaining the primary alcohol
derivative 6. The methylation of this group (compound 7) was
performed upon treatment with methyl triflate in the presence
of an excess of 2,6-di-tert-butylpyridine, while its acetylation,
performed under standard conditions (acetic anhydride, pyri-
dine), yielded compound 8 in quantitative amounts (Scheme
1).
Finally, we turned out our attention to reactions of the
carbon-carbon double bond (Scheme 2). Its oxidative cleavage
(KMnO4/NaIO4 in t-BuOH/Na2CO3) afforded the carboxylic
acid derivative 9 in high yield (80%). A portion of compound
9 was subsequently methylated with diazomethane, obtaining
a quantitative conversion into compound 10. The double bond
of plakortin (1) was also epoxidized with meta-chloro-perben-
zoic acid in dry CH2Cl2 and, as expected, this reaction afforded
two different epoxides, 11 and 12, deriving from the syn
approach of the reagent from both sides of the trans double
bond. The trans geometry of the epoxide ring was unambigu-
ously demonstrated for both 11 and 12 through the 2D ROESY
spectrum: cross-peaks corresponding to the spatial coupling of
H-9 with H2-11 were detected in both cases (11: ä 2.44 with
ä 1.58; 12: ä 2.52 with ä 1.55). Given the unsuitability of X-ray
structure determination, due to the oily nature of the compounds,
determination of the correct absolute configuration at the epoxide
carbons of 11 and 12 required a different strategy. In particular,
a reaction that opened the epoxide ring and left (preferably)
one secondary alcohol group, to be subjected to the Mosher
methodology, appeared appropriate. To this end, we first
attempted an application of the recently reported mild epoxide
ring opening by reaction with methanol, catalyzed by copper(II)
tetrafluoroborate,9 but, unfortunately, a complex mixture of
products, apparently coming from concomitant reactions of the
cycloperoxide bond, was obtained. Thus, we decided to turn to
the complete reduction of one of the two epoxides (12), by using
LiAlH4 in dry ether. In this way, only two tetraol derivatives,
13 and 14, were obtained, and inspection of their NMR spectra
confirmed that they actually were two regioisomers differing
for the position of only one hydroxyl group (at C-10 and at
C-9, respectively). Compound 13 was then esterified by using
an excess of (R)- and (S)-MTPA chloride in dry pyridine, thus
obtaining the MTPA triester derivatives 15 and 16, respectively.
These were analyzed following the modified Mosher method,10
and the S configuration was thus assigned at C-10 of 13.
Consequently, the S configuration could be assigned at C-10
of 12 and, given the trans geometry of the epoxide ring in 12,
its absolute configuration was determined as 9S,10S. On account
of the enantiomeric relationship existing between the epoxide
carbons of 11 and 12, we assigned the absolute configuration
of the corresponding chiral carbons in 11 as 9R,10R.
Results and Discussion
The new semisynthetic plakortin derivatives 5-12 were tested
for their in vitro antimalarial activity, using the pLDH assay,
against D10 (chloroquine sensitive, CQ-S) and W2 (chloroquine
resistant, CQ-R) strains of P. falciparum. Results are reported
in Table 1.
First, it is noteworthy the complete inefficacy of diol 5,
demonstrating that, as reported for artemisinins, the cyclo-
peroxide functionality plays a crucial role in the antimalarial
activity of plakortin derivatives. Second, all the new semi-
Scheme 1. Reactions at the Oxygenated Carbons of Plakortin
(1) Yielding Compounds 5-8
Scheme 2. Reactions at the Carbon-Carbon Double Bond of
Plakortin (1) Yielding Compounds 9-12 and Strategy for
Determination of Absolute Configuration at the Epoxide
Carbons of 11 and 12
Endoperoxide DeriVatiVes from Marine Organisms Journal of Medicinal Chemistry, 2006, Vol. 49, No. 24 7089
synthetic compounds are more active on W2 (CQ-R strains)
than on D10 (CQ-S strains), with the exception of 9 which
presents similar activity on both strains. Going into detail, some
interesting considerations can be made: (i) the substitution of
the ester function (1) with different groups such as hydroxy
(6), methoxy (7), and acetoxy (8) does not affect activity and
selectivity for the tested strains of Plasmodium falciparum;
moreover, these compounds present a collinearity between the
activity variation on D10 (CQ-S strains) and W2 (CQ-R strains);
(ii) changes on the “Western” alkyl side chain appear to have
a more significant effect on the antimalarial activity, differently
affecting activity against CQ-S and CQ-R strains. The decreased
activity of compound 9 against both P. falciparum strains
suggests unfavorable parasite penetration properties due to the
presence of the free carboxylic function. Accordingly, the
esterification of the carboxylic group (10) determines a slight
overall improvement in the antimalarial activity. On the other
hand, compounds 11 and 12 show an activity similar to that of
9 on CQ-S strains, while they exhibit a 2-fold increase of activity
against CQ-R strains. Interestingly, some data available in the
literature for plakortin-related molecules appear to strengthen
the observation that changes on the “Western” alkyl side chain
can significantly influence the antimalarial activity. Compounds
17 and 18 (Figure 2), which are close analogues of plakortin
(1), are much less active than 1.11 In particular, compound 17
shows a reduced activity (IC50 1.9 íM) on W2 (CQ-R strain),
while compound 18, differing only for the absence of the ketone
group, is practically inactive (IC50 > 10 íM) on W2.11
In order to investigate the role played by the conformational
parameters on the antimalarial activity of plakortin-related
endoperoxides, we performed a full computational analysis on
the new derivatives 6-12 as well as on the reference compounds
1-46-8 and on the plakortin-related compounds 17 and 18.11
The resulting conformers can been grouped into four families
(Figure 3) in relation to the dioxane ring conformations, named
chair A, chair B, boat A, and boat B (Table 2), demonstrating
a strong preference for the chair conformations, in agreement
with the previously observed conformational behavior of the
1,2 dioxane ring system.12 It can be noted that all the molecules
exhibiting a good antimalarial activity (i.e., IC50 < 1 íM on
CQ-R strains, 1-4, 6-12) present the same conformational
preference of the dioxane ring (Chair A, Table 2). It is
noteworthy that, while the epimerization at C-3 (3 and 4) does
not affect the conformation of the dioxane ring, the change in
the conformational behavior (Table 2) of compounds 17 and
18 can be attributed to the concomitant epimerization at C-4,
which changes the relative orientation of the ethyl chain with
respect to the “Western” alkyl side chain (Figure S1, Supporting
Information). The importance of the endoperoxide ring confor-
mation is strengthened by comparison with the structure of
artemisinin. Indeed, the most favorite conformation (Chair A)
of the dioxane ring of plakortin (1) and its active derivatives
overlaps well with the peroxide ring-constrained conformation
of artemisinin (Figure 4). On the other hand, the complete lack
of activity of compound 18 with respect to 17 confirms that
small changes in the “Western” alkyl side chain of plakortin-
related structures can markedly influence the antimalarial
activity, even if the molecules show the same conformation of
the dioxane ring.
Conclusions
The mechanism of action of plakortin as well as that of related
simple endoperoxides is still a matter of debate. However, the
present study, besides confirming the crucial role of the
cycloperoxide functionality, took into consideration other
structural features critical for antimalarial activity: (i) the
“Western” alkyl side chain, (ii) the dioxane ring conformation,
(iii) the absolute configuration of the sterogenic carbons on the
1,2-dioxane ring, only when affecting the bioactive dioxane ring
conformation. This latter observation, together with the com-
Table 1. In Vitro Antimalarial Activity of Plakortin (1) and of
Semisynthetic Derivatives 6-12 against D10 (CQ-S) and W2 (CQ-R)
Strains of Plasmodium falciparuma
a Data are means ( SD of four different experiments in triplicate.
Compound 5 (in which the cycloperoxide function is replaced by the 3,6-
diol function) proved to be completely inactive (IC50 > 20 íM) against
both strains.
Figure 2. Plakortin-related molecules isolated from other sponges.
Figure 3. Lowest energy minima of each 1,2-dioxane ring conforma-
tion family of plakortin. Carbons are in green (chair A), cyan (chair
B), orange (boat A), and yellow (boat B); oxygens are in red. All
hydrogens are omitted for clarity. Parallel families were also found
for the other 1,2-dioxanes investigated.
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parable activity of the diastereomers 11 and 12, suggests the
absence of a stereospecific interaction with the putative anti-
malarial molecular target. A thorough investigation on the
mechanism of action of plakortins, which is ongoing in our
laboratories, could better clarify the role of the “Western” side
chain and of the dioxane ring conformation in modulating the
activity of these simplified cycloperoxide scaffolds, providing
further valuable information to optimize the antimalarial profile
of novel, synthetically affordable, endoperoxides of the plakortin
series.
Experimental Section
General Methods. Optical rotations (CHCl3) have been mea-
sured on a Perkin-Elmer 192 polarimeter equipped with a sodium
lamp (ì ) 589 nm) and a 10-cm microcell. Low-resolution ESIMS
(positive ions) experiments were performed on an Applied Bio-
system API 2000 triple quadrupole mass spectrometer. The spectra
were recorded by infusion into the ESI source using MeOH as the
solvent. Low- and high-resolution EI mass spectra (70 eV, direct
inlet) were performed on a VG Prospec (FISONS) mass spectrom-
eter. 1H (500 MHz) and 13C (125 MHz) NMR spectra were
determined on a Varian UnityInova 500 NMR spectrometer;
chemical shifts are referenced to the residual solvent signal
(CDCl3: äH ) 7.26, äC ) 77.0). Homonuclear 1H connectivities
were determined by COSY experiments. Through-space 1H con-
nectivities were demonstrated using a 2D ROESY experiments with
a mixing time of 500 ms. One bond heteronuclear 1H-13C
connectivities were determined with the HSQC experiment. Two
and three bond 1H-13C connectivities were determined by HMBC
experiments optimized for a 3JCH of 8.0 Hz. Medium-pressure liquid
chromatography (MPLC) was performed using a Bu¨chi 861
apparatus using Merck SI60 (230-400 mesh) stationary phase. High
performance liquid chromatography (HPLC) separations in isocratic
mode were achieved on a Beckmann apparatus equipped with
refractive index detector and with Phenomenex LUNA SI60 (250
 4 mm) columns.
Animal Material, Extraction, and Isolation. A specimen of
Plakortis simplex was collected in July 2002 along the coasts of
Bahamas. A voucher specimen is deposited at the Dipartimento di
Chimica delle Sostanze Naturali, Italy with the ref nï. 02-10. The
organism was immediately frozen after collection and kept frozen
until extraction, when the sponge (43 g, dry weight after extraction)
was homogenized and extracted with methanol (4  500 mL) and
with chloroform (4  500 mL). The methanol extract was initially
partitioned between H2O and n-BuOH, and then the organic phase
was combined with the CHCl3 extract and concentrated in vacuo
to afford a brown oil (22.1 g). This was subjected to chromatog-
raphy on a column packed with RP18 silica gel and eluted with
H2O/MeOH 9:1 (A1), H2O/ MeOH 7:3 (A2), H2O/MeOH 4:6 (A3),
H2O/MeOH 2:8 (A4), and MeOH (A5). Fractions A4 and A5 were
combined (6.5 g) and further chromatographed by MPLC (SiO2
230-400 mesh; solvent gradient system of increasing polarity from
n-hexane to MeOH). MPLC fractions eluted with n-hexane/EtOAc
9:1 were rechromatographed over SiO2 column, using a solvent
gradient system from n-hexane to n-hexane/EtOAc 8:2, to afford
plakortin (1, 1.18 g).
Reduction of Plakortin Cycloperoxide Bond. Plakortin (1, 35
mg, 0.11 mmol) in 200 íL of dry ether was treated with 200 íL of
acetic acid and an excess (80 mg) of Zn dust and then stirred
vigorously for 24 h at room temperature. After confirmation of
disappearance of the starting material by TLC, the solution was
neutralized with Na2CO3 and the solid removed by filtration. The
solvent was then evaporated, and the obtained product was
partitioned between H2O and CHCl3. The organic phase contained
compound 5 (29 mg, 0.092 mmol, yield 83.4%), in a pure state.
Compound 5: Colorless oil. [R]D25 -5 (c ) 0.10 in CHCl3).
ESMS: m/z 315 [M + H]+, 337 [M + Na]+. EIMS: m/z 296 (M
- 18), 281 (M - 33). HREIMS: m/z 314.2467, calcd for C18H34O4
m/z 314.2457. 1H NMR (CDCl3): ä 5.53 (H-10, dt, J ) 15.2, 6.2
Table 2. Conformational Preference of 1,2-Dioxane Ring for Reference
Compounds 1-4, New Semisynthetic Derivatives 6-12, and
Plakortin-Related Compounds 17 and 18
compd
1,2-dioxane ring
conformation
% of conformers
within 5 kcal/ mol
from GMa
¢E from the GMa
of the lowest energy
conformer (kcal/ mol)
1 chair A 92 0.00
chair B 7 3.56
boat A 1 4.62
boat B - >5
2 chair A 82 0.00
chair B 14 2.09
boat A 4 4.40
boat B - >5
3 chair A 95 0.00
chair B 2.5 4.59
boat A 2.5 4.07
boat B - >5
4 chair A 98 0.00
chair B - >5
boat A 2 4.49
boat B - >5
6 chair A 93 0.00
chair B 7 4.39
boat A - >5
boat B - >5
7 chair A 86 0.00
chair B 14 3.03
boat A - >5
boat B - >5
8 chair A 90 0.00
chair B 10 3.53
boat A - >5
boat B - >5
9 chair A 77 0.00
chair B 18 2.27
boat A 5 4.41
boat B - >5
10 chair A 97 0.00
chair B 3 4.93
boat A - >5
boat B - >5
11 chair A 79 0.00
chair B 21 3.61
boat A - >5
boat B - >5
12 chair A 84 0.00
chair B 16 3.07
boat A - >5
boat B - >5
17 chair A 15 2.73
chair B 78 0.00
boat A - >5
boat B 7 4.64
18 chair A 30 2.41
chair B 64 0.00
boat A - >5
boat B 6 4.82
a Global minimum energy conformer.
Figure 4. Superimposition of the lowest energy conformer of plakortin
(1) on artemisinin X-ray structure (CSDS code: QNGHSU). Carbons
are in green for plakortin (1) and in yellow for artemisinin; oxygens
are in red. All hydrogens are omitted for clarity.
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Hz); 5.21 (H-9, dd, J ) 15.2, 9.0 Hz); 4.16 (H-3, dt, J ) 10.4, 2.1
Hz); 3.70 (H3-18, s); 2.46 (H-2a, dd, J ) 15.9, 10.4 Hz); 2.34 (H-
2b, dd, J ) 15.9, 2.1 Hz); 2.13 (H-8, m); 2.03 (H2-11, q, J ) 6.2
Hz); 1.91 (H-4, m); 1.67 (H-5a, dd, J ) 13.5, 9.8 Hz); 1.55 (H-7a,
overlapped); 1.53 (H-7b, overlapped); 1.38 (H-13a, m); 1.35 (H-
5b, overlapped); 1.27 (H-16a, m); 1.21 (H-13b, m); 1.17 (H3-15,
s); 1.13 (H-16b, m); 0.98 (H3-12, t, J ) 6.2 Hz); 0.92 (H3-17, t, J
) 7.3 Hz); 0.84 (H3-14, t, J ) 6.3 Hz). 13C NMR (CDCl3): ä
173.7 (C-1); 134.8 (C-9); 133.8 (C-10); 73.0 (C-6); 70.6 (C-3);
51.7 (OCH3); 49.7 (C-7); 40.8 (C-8); 40.7 (C-5); 40.5 (C-4); 36.6
(C-2); 29.7 (C-13); 26.8 (C-15); 26.4 (C-16); 25.6 (C-11); 13.7
(C-12); 12.3 (C-17); 11.5 (C-14).
Reduction of the Ester Group of Plakortin. Plakortin (1, 100
mg, 0.32 mmol) was dissolved in 3.0 mL of dry THF under argon
flow at 0 °C, and then 450 íL of a 2 M solution of LiBH4 in THF
(0.9 mmol) and 30 íL of dry MeOH were added dropwise to the
solution. The reaction was kept under stirring for 2 h at 0 °C. Then,
30 íL of 1 M aqueous NaOH was added to the obtained mixture,
which was partitioned between water and CHCl3. The organic phase,
dried with Na2SO4 and concentrated in vacuo, was purified by
HPLC (LUNA SI60 250  4 eluent n-hexane/EtOAc 75:25)
affording pure compound 6 (78 mg, 0.28 mmol, 87.5% yield).
Compound 6: Colorless oil. [R]D25 +55 (c ) 0.10 in CHCl3).
ESMS: m/z 285 [M + H]+, 307 [M + Na]+. EIMS: m/z 284 (M),
266 (M - 18). HREIMS: m/z 284.2339, calcd for C17H32O3 m/z
284.2351. 1H NMR (CDCl3): ä 5.36 (H-10, dt, J ) 16.3, 6.6 Hz);
5.09 (H-9, dd, J ) 16.3, 9.5 Hz); 4.08 (H-3, m); 3.81 (H2-1, t, J )
6.0 Hz); 2.16 (H-2a, overlapped); 2.08 (H-4, overlapped); 2.03 (H-
8, overlapped); 1.99 (H2-11, q, J ) 6.6 Hz); 1.49 (H-2b, ddd, J )
13.8, 6.0, 4.3 Hz); 1.44 (H-7a, overlapped); 1.40 (H-5a, overlapped);
1.37 (H3-15, s); 1.36 (H-16a, overlapped); 1.32 (H-5b, overlapped);
1.27 (H-13a, m); 1.23 (H-7b, overlapped); 1.15 (H-16b, overlapped);
1.15 (H-13b, overlapped); 0.95 (H3-12, t, J ) 6.3 Hz); 0.87 (H3-
14, t, J ) 6.6 Hz); 0.79 (H3-17, t, J ) 6.6 Hz). 13C NMR (CDCl3):
ä 134.3 (C-9); 132.0 (C-10); 81.5 (C-6); 80.5 (C-3); 60.5 (C-1);
46.4 (C-7); 39.9 (C-8); 34.7 (C-4); 34.3 (C-5); 29.9 (C-16); 29.2
(C-13); 26.8 (C-2); 25.2 (C-11); 21.0 (C-15); 13.7 (C-12); 11.1
(C-17); 11.0 (C-14).
Methylation of Compound 6. Compound 6 (25 mg, 0.088
mmol) was dissolved in dry CH2Cl2 (3 mL) at 0 °C, and an excess
of 2,6-di-tert-butylpyridine (130 íL) and 50 íL (0.44 mmol) of
methyl trifluoromethansolfonate was added dropwise to the solution.
The reaction mixture was left under stirring overnight and then
treated with saturated NaHCO3. The organic phase, dried with
Na2SO4 and concentrated in vacuo, was purified by HPLC (LUNA
SI60 250  4 eluent n-hexane/EtOAc 85:15) affording pure
compound 7 (20 mg, 0.067 mmol, 76.1% yield).
Compound 7: Colorless oil. [R]D25 +75 (c ) 0.10 in CHCl3).
ESMS: m/z 299 [M + H]+, 321 [M + Na]+. EIMS: m/z 298 (M),
266 (M - 32). HREIMS: m/z 298.2500, calcd for C18H34O3 m/z
298.2509. 1H NMR (CDCl3): ä 5.36 (H-10, dt, J ) 16.3, 6.6 Hz);
5.10 (H-9, dd, J ) 16.3, 9.5 Hz); 4.06 (H-3, m); 3.53 (H2-1, m);
3.34 (OCH3, s) 2.16 (H-2a, overlapped); 2.12 (H-2b, overlapped);
2.09 (H-4, overlapped); 2.03 (H-8, overlapped); 1.99 (H2-11, q, J
) 6.6 Hz); 1.50 (H-7a, overlapped); 1.43 (H-5a, dd, J ) 13.8, 4.3
Hz); 1.37 (H3-15, s); 1.36 (H-16a, overlapped); 1.32 (H-7b,
overlapped); 1.27 (H-13a, m); 1.24 (H-5b, dd, J ) 13.8, 6.9 Hz);
1.15 (H-13b, overlapped); 1.14 (H-16b, overlapped); 0.96 (H3-12,
t, J ) 6.6 Hz); 0.87 (H3-14, t, J ) 6.6 Hz); 0.80 (H3-17, t, J ) 6.6
Hz). 13C NMR (CDCl3): ä 134.3 (C-9); 131.4 (C-10); 81.1 (C-6);
79.0 (C-3); 69.4 (C-1); 58.8 (OCH3); 46.5 (C-7); 40.1 (C-8); 34.8
(C-4); 34.7 (C-5); 29.8 (C-13); 29.6 (C-16); 25.5 (C-2); 25.0 (C-
11); 21.4 (C-15); 13.8 (C-12); 11.3 (C-14); 11.1 (C-17).
Acetylation of Compound 6. Compound 6 (20 mg, 0.070 mmol)
was dissolved in dry pyridine (1 mL) and treated with Ac2O (1
mL). After standing overnight, the reaction was worked up by
addition of a few drops methanol to destroy the excess Ac2O, water
(ca. 5 mL), and EtOAc (ca. 15 mL). The organic phase was washed
sequentially with 2 N H2SO4, saturated NaHCO3, and brine. After
drying (Na2SO4) and removal of the solvent, 22.0 mg (0.069 mmol)
of compound 8 was obtained.
Compound 8: Colorless oil. [R]D25 +47 (c ) 0.10 in CHCl3).
ESMS: m/z 327 [M + H]+, 350 [M + Na]+. EIMS: m/z 326 (M),
266 (M - CH3COOH). HREIMS: m/z 326.2466, calcd for
C19H34O4 m/z 326.2457. 1H NMR (CDCl3): ä 5.36 (H-10, dt, J )
16.3, 6.6 Hz); 5.09 (H-9, dd, J ) 16.3, 9.6 Hz); 4.27 (H-1a, m);
4.21 (H-1b, m); 4.04 (H-3, m); 2.23 (H-2a, m); 2.10 (H-4,
overlapped); 2.03 (H-8, overlapped); 2.03 (OCOCH3, s); 1.99 (H2-
11, q, J ) 6.6 Hz); 1.59 (H-2b, overlapped); 1.41 (H-7a,
overlapped); 1.37 (H3-15, s); 1.36 (H-16a, overlapped); 1.34 (H-
5a, overlapped); 1.29 (H-5b, overlapped); 1.26 (H-13a, overlapped);
1.15 (H-7b, overlapped); 1.15 (H-16b, overlapped); 1.13 (H-13b,
overlapped); 0.96 (H3-12, t, J ) 6.6 Hz); 0.88 (H3-14, t, J ) 6.6
Hz); 0.80 (H3-17, t, J ) 6.6 Hz). 13C NMR (CDCl3): ä 171.1
(CH3CO); 134.2 (C-9); 131.3 (C-10); 81.2 (C-6); 78.6 (C-3); 61.7
(C-1); 46.5 (C-7); 40.1 (C-8); 34.8 (C-4); 34.5 (C-5); 30.3 (C-16);
29.8 (C-13); 25.4 (C-11); 23.9 (C-2); 21.5 (CH3CO); 21.1 (C-15);
14.0 (C-12); 11.4 (C-14); 11.0 (C-17).
Oxidative Cleavage of Plakortin. To a solution of plakortin
(120 mg, 0.385 mmol) in 40 mL of t-BuOH were added 26 mL of
0.04 M Na2CO3 and 150 mL of an aqueous solution 0.023 M in
KMnO4 and 0.09 M in NaIO4. The reaction was allowed to proceed
at 37 °C for 20 h under stirring. After acidification with 5 N H2SO4,
the solution was decolorized with a saturated solution of oxalic
acid and extracted with diethyl ether (200 mL, twice). Combined
organic phases were dried over Na2SO4, filtered, and then concen-
trated in vacuo. The obtained fraction was purified by HPLC
(LUNA, SI60, eluent n-hexane/EtOAc 65:35) yielding compound
9 (90 mg, 0.289 mmol, 75% yield) in the pure state.
Compound 9: Amorphous solid. [R]D25 + 80 (c ) 0.10 in
CHCl3). ESMS: m/z 303 [M + H]+, 325 [M + Na]+. EIMS: m/z
302 (M). HREIMS: m/z 302.1735, calcd for C15H26O6 m/z
302.1729. 1H NMR (CDCl3): ä 4.50 (H-3, m); 3.70 (OCH3, s);
3.01 (H-2a, dd, J ) 15.9, 10.4 Hz); 2.50 (H-8, m); 2.36 (H-2b, dd,
J ) 15.9, 2.1 Hz); 2.19 (H-4, m); 2.02 (H-7a, dd, J ) 13.5, 9.8
Hz); 1.62 (H-10a, m); 1.54 (H-10b, overlapped); 1.50 (H-7b,
overlapped); 1.45 (H-5a, overlapped); 1.37 (H3-12, s); 1.34 (H-5b,
overlapped); 1.22 (H-13a, m); 1.14 (H-13b, m); 0.92 (H3-11, t, J
) 6.6 Hz); 0.90 (H3-14, t, J ) 6.6 Hz). 13C NMR (CDCl3): ä
181.9 (C-9); 172.2 (C-1); 80.0 (C-6); 78.9 (C-3); 51.9 (OCH3); 42.8
(C-7); 41.6 (C-8); 34.7 (C-4); 34.4 (C-5); 31.3 (C-2); 27.1 (C-10);
24.9 (C-13); 20.9 (C-12); 11.2 (C-11); 11.0 (C-14).
Methylation of Compound 9. To 40 mg of compound 9 (0,132
mmol) was added dropwise a saturated solution of CH2N2 in Et2O.
After removal of the organic solvent, the residue was purified by
HPLC (eluant n-hexane/EtOAc 95:5, flow 0.8 mL/min) affording
pure compound 10 (41 mg, 0.130 mmol).
Compound 10: Colorless oil. [R]D25 + 108 (c ) 0.10 in CHCl3).
ESMS: m/z 317 [M + H]+, 339 [M + Na]+. EIMS: m/z 316 (M).
HREIMS: m/z 316.1895, calcd for C16H28O6 m/z 316.1886. 1H
NMR (CDCl3): ä 4.50 (H-3, m); 3.70 (OCH3, s); 3.69 (OCH3, s);
3.00 (H-2a, dd, J ) 15.9, 10.4 Hz); 2.48 (H-8, m); 2.36 (H-2b, dd,
J ) 15.9, 2.1 Hz); 2.19 (H-4, m); 2.02 (H-7a, dd, J ) 13.5, 9.8
Hz); 1.60 (H-10a, m); 1.52 (H-7b, overlapped); 1.48 (H-10b,
overlapped); 1.44 (H-5a, overlapped); 1.35 (H3-12, s); 1.34 (H-5b,
overlapped); 1.22 (H-13a, m); 1.14 (H-13b, m); 0.90 (H3-14, t, J
) 6.6 Hz); 0.88 (H3-11, t, J ) 6.6 Hz). 13C NMR (CDCl3): ä
176.8 (C-9); 172.2 (C-1); 80.1 (C-6); 78.7 (C-3); 51.9 (OCH3); 51.6
(OCH3); 41.9 (C-7); 41.6 (C-8); 34.7 (C-4); 34.3 (C-5); 31.3 (C-
2); 27.5 (C-10); 25.0 (C-13); 21.0 (C-12); 11.5 (C-11); 11.0 (C-
14).
Epoxidation of Plakortin. Plakortin (110 mg, 0.353 mmol) was
dissolved in 4 mL of dry CH2Cl2, and 84 mg of meta-chloroper-
benzoic acid (0.494 mmol) was added to the solution that was then
stirred overnight at room temperature. Subsequently, the reaction
mixture was partitioned between CHCl3 and saturated aqueous
NaHCO3. The organic phase, dried and concentrated in vacuo, was
then purified by HPLC (LUNA, SI60, eluent n-hexane/EtOAc 9:1)
yielding compounds 11 (41 mg, 0.125 mmol, 35% yield) and 12
(45 mg, 0.137 mmol, 39% yield) in the pure state.
Compound 11: Colorless oil. [R]D25 +63 (c ) 0.10 in CHCl3).
ESMS: m/z 329 [M + H]+, 351 [M + Na]+. EIMS: m/z 328 (M),
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312 (M - 16). HREIMS: m/z 328.2257, calcd for C18H32O5 m/z
328.2250. 1H NMR (CDCl3): ä 4.51 (H-3, m); 3.71 (OCH3, s);
2.95 (H-2a, dd, J ) 15.7, 10.5 Hz); 2.73 (H-10, bd, J ) 1.7 Hz);
2.52 (H-9, dd, J ) 7.0, 1.7 Hz); 2.37 (H-2b, dd, J ) 15.7, 3.5 Hz);
2.20 (H-4, m); 1.60 (H-7a, overlapped); 1.58 (H-5a, overlapped);
1.56 (H-8, overlapped); 1.55 (H2-11, overlapped); 1.47 (H-7b,
overlapped); 1.45 (H-5b, overlapped); 1.38 (H3-15, s); 1.36 (H-
13a, overlapped); 1.34 (H-16a, overlapped); 1.21 (H-13b, m); 1.15
(H-16b, m); 0.99 (H3-12, t, J ) 7.8 Hz); 0.94 (H3-14, t, J ) 7.8
Hz); 0.92 (H3-17, t, J ) 7.8 Hz). 13C NMR (CDCl3): ä 171.9 (C-
1); 80.4 (C-6); 78.6 (C-3); 62.4 (C-10); 59.6 (C-9); 51.7 (OCH3);
41.8 (C-7); 36.8 (C-8); 35.3 (C-5); 34.9 (C-4); 31.4 (C-2); 26.2
(C-11); 25.1 (C-13); 25.0 (C-16); 21.5 (C-15); 11.0 (C-17); 10.7
(C-14); 9.9 (C-12).
Compound 12: Colorless oil. [R]D25 +48 (c ) 0.10 in CHCl3).
ESMS: m/z 329 [M + H]+, 351 [M + Na]+. EIMS: m/z 328 (M),
312 (M - 16). HREIMS: m/z 328.2242, calcd for C18H32O5 m/z
328.2250. 1H NMR (CDCl3): ä 4.51 (H-3, m); 3.71 (OCH3, s);
3.02 (H-2a, dd, J ) 15.7, 9.6 Hz); 2.73 (H-10, dt, J ) 5.2, 1.7
Hz); 2.44 (H-9, dd, J ) 7.8, 1.7 Hz); 2.38 (H-2b, dd, J ) 15.7, 3.5
Hz); 2.18 (H-4, m); 1.64 (H-7a, dd, J ) 14.0, 4.4 Hz); 1.58 (H-5a,
overlapped); 1.57 (H2-11, overlapped); 1.56 (H-8, overlapped); 1.56
(H-13a, overlapped); 1.47 (H-7b, dd, J ) 14.0, 4.4 Hz); 1.45 (H-
5b, m); 1.36 (H3-15, s); 1.33 (H-13b, m); 1.20 (H-16a, overlapped);
1.18 (H-16b, overlapped); 1.00 (H3-12, t, J ) 7.0 Hz); 0.91 (H3-
14, t, J ) 7.0 Hz); 0.90 (H3-17, t, J ) 7.0 Hz). 13C NMR (CDCl3):
ä 171.9 (C-1); 80.4 (C-6); 78.9 (C-3); 62.7 (C-9); 61.0 (C-10);
52.0 (OCH3); 43.7 (C-7); 38.2 (C-8); 36.3 (C-5); 34.8 (C-4); 31.3
(C-2); 25.2 (C-11); 25.1 (C-13); 24.8 (C-16); 20.2 (C-15); 11.2
(C-17); 11.2 (C-14); 10.2 (C-12).
Reduction of Compound 12. Compound 12 (28 mg, 0.085
mmol) was dissolved in dry diethyl ether, 10 equiv of LiAlH4 was
added, and the solution was allowed to stir for 3 h at room
temperature. After completion of the reaction, H2O was added and
the solution extracted with chloroform. Evaporation in vacuo of
the organic phase yielded a mixture that was purified by HPLC
(LUNA, SI60, eluent EtOAc) yielding compounds 13 (13 mg, 0.043
mmol, 51% yield) and 14 (10 mg, 0.033 mmol, 39% yield) in the
pure state.
Compound 13: Amorphous solid. [R]D25 +15 (c ) 0.10 in
CHCl3). ESMS: m/z 305 [M + H]+, 327 [M + Na]+. EIMS: m/z
286 (M - 18), 304 (M). HREIMS: m/z 304.2607, calcd for
C17H36O4 m/z 304.2614. 1H NMR (CDCl3): 4.18 (H-3, m); 4.16
(H-10, m); 3.83 (H2-1, t, J ) 6.0 Hz); 2.19 (H-2a, m); 1.97 (H-8,
m); 1.91 (H-4, m); 1.75 (H-9a, overlapped); 1.73 (H-11a, over-
lapped); 1.68 (H-9b, overlapped); 1.67 (H-5a, dd, J ) 13.5, 9.8
Hz); 1.57 (H-11b, overlapped); 1.55 (H2-7, overlapped); 1.52 (H-
2a, ddd, J ) 13.8, 6.0, 4.3 Hz); 1.39 (H-13a, m); 1.36 (H-5b,
overlapped); 1.27 (H-16a, m); 1.21 (H-13b, m); 1.19 (H3-15, s);
1.13 (H-16b, m); 0.93 (H3-12, t, J ) 7.3 Hz); 0.92 (H3-17, t, J )
7.3 Hz); 0.87 (H3-14, t, J ) 7.3 Hz).
Compound 14: Amorphous solid. [R]D25 +19 (c ) 0.10 in
CHCl3). ESMS: m/z 305 [M + H]+, 327 [M + Na]+. EIMS: m/z
286 (M - 18), 304 (M). HREIMS: m/z 304.2627, calcd for
C17H36O4 m/z 304.2614. 1H NMR (CDCl3): 4.22 (H-9, m); 4.18
(H-3, m); 3.83 (H2-1, t, J ) 6.0 Hz); 2.18 (H-2a, m); 2.00 (H-8,
m); 1.92 (H-4, m); 1.67 (H-5a, dd, J ) 13.5, 9.8 Hz); 1.65 (H-10a,
overlapped); 1.62 (H-10b, overlapped); 1.58 (H2-7, overlapped);
1.52 (H-2a, ddd, J ) 13.8, 6.0, 4.3 Hz); 1.39 (H-13a, m); 1.36
(H-5b, overlapped); 1.27 (H2-11, overlapped); 1.27 (H-16a, over-
lapped); 1.21 (H-13b, m); 1.19 (H3-15, s); 1.13 (H-16b, m); 0.92
(H3-17, t, J ) 7.3 Hz); 0.89 (H3-12, t, J ) 7.3 Hz); 0.88 (H3-14, t,
J ) 7.3 Hz).
Preparation of MTPA Esters of Compound 13. Compound
13 (4 mg) was dissolved in 1.0 mL of dry pyridine, treated with
(-)-MTPA chloride (15 íL) and N,N-dimethylaminopyridine
(DMAP, a spatula tip), and then maintained at room temperature
under stirring overnight. After removal of the solvent, the reaction
mixture was purified by HPLC on an SI60 column (eluent n-hexane/
EtOAc 95:5), affording (S)-MTPA ester 15 in a pure state (4.4 mg).
Using (+)-MTPA chloride, the same procedure afforded (R)-MTPA
ester 16 in the same yield.
(S)-MTPA ester (15): Amorphous solid. ESI-MS (glycerol
matrix, positive ions): m/z 975 [M + Na]+. 1H NMR (CDCl3): ä
7.35 and 7.45 (MTPA phenyl protons); 5.73 (H-10, m); 5.63 (H-3,
m); 4.29 (H2-1, m); 3.59 (MTPA OCH3); 2.20 (H-2a, m); 2.00 (H-
2b, m); 1.84 (H-8, overlapped); 1.82 (H-9a, overlapped); 1.75 (H-
9b, m); 1.62 (H2-11, m); 1.60 (H-4, m); 1.18 (H-5a, overlapped);
1.12 (H-16a, overlapped); 1.11 (H-7a, overlapped); 1.05 (H2-13,
overlapped); 1.03 (H-7b, overlapped); 0.98 (H-5b, overlapped); 0.95
(H-16b, overlapped); 0.86 (H3-15, s); 0.63 (H3-12, t, J ) 7.3 Hz);
0.62 (H3-17, t, J ) 7.3 Hz); 0.55 (H3-14, t, J ) 7.3 Hz).
(R)-MTPA ester (16): Amorphous solid. ESI-MS (glycerol
matrix, positive ions): m/z 975 [M + Na]+. 1H NMR (CDCl3): ä
7.32 and 7.55 (MTPA phenyl protons); 5.71 (H-10, m); 5.68 (H-3,
m); 4.25 (H2-1, m); 3.59 (MTPA OCH3); 2.17 (H-2a, m); 1.95 (H-
2b, m); 1.80 (H-9a, overlapped); 1.76 (H-8, overlapped); 1.73 (H-
4, m); 1.70 (H-9b, m); 1.68 (H-11a, m); 1.65 (H-11b, m); 1.36
(H-5a, dd, J ) 14.3, 6.7 Hz); 1.25 (H-16a, overlapped); 1.21 (H-
7a, overlapped); 1.13 (H-7b, overlapped); 1.12 (H-16b, overlapped);
1.12 (H2-13, overlapped); 1.11 (H-5b, overlapped); 1.00 (H3-15,
s); 0.73 (H3-17, t, J ) 7.3 Hz); 0.72 (H3-12, t, J ) 7.3 Hz); 0.55
(H3-14, t, J ) 7.3 Hz).
Measurement of in Vitro Antimalarial Activity. Plasmodium
falciparum cultures were carried out according to Trager and
Jensen’s method with slight modifications.13 The CQ-sensitive,
moderately mefloquine-resistant clone D10 and the CQ-resistant,
mefloquine-susceptible clone W2 were maintained at 5% hemeat-
ocrit (human type A-positive red blood cells) in complete culture
medium at 37 °C. Complete medium contained RPMI 1640 medium
(Euroclone) with the addition of 10% heat-inactivated A-positive
human plasma, 20 mM HEPES (Euroclone), 2 mM glutamine
(Euroclone). All the cultures were maintained in a standard gas
mixture consisting of 1% O2, 5% CO2, 94% N2. When parasitemia
exceeded 5%, subcultures were taken; the culture medium was
changed every second day.
Compounds were dissolved in either water (chloroquine) or
DMSO (compounds 5-12) and then diluted with medium to achieve
the required concentrations (in all cases the final concentration
contained <1% DMSO, which was found to be nontoxic to the
parasite). Drugs were placed in 96-well flat-bottom microplates
(Costar # 3596) and serial dilutions made. Asynchronous cultures
with parasitemia of 1-1.5% and 1% final hemeatocrit were
aliquoted into the plates and incubated for 72 h at 37 °C. Parasite
growth was determined spectrophotometrically (OD650) by measur-
ing the activity of the parasite lactate dehydrogenase (LDH),
according to a modified version of the method of Makler14,15 in
control and drug-treated cultures. Antimalarial activity was ex-
pressed as the 50% inhibitory concentrations (IC50, íM); each IC50
value presented in Table 1 is the mean and standard deviation of
four separate experiments performed in triplicate.
Molecular Modeling. Molecular modeling calculations were
performed on SGI Origin 200 8XR12000, while molecular modeling
graphics were carried out on SGI Octane 2 and Octane workstations.
Plakortin (1) and compounds 2-12, 17, 18 were built using the
Insight 2005 Builder module. The estimation of apparent pKa values
of the newly designed compounds were calculated by using the
ACD/pKa DB version 9.00 software (Advanced Chemistry Devel-
opment Inc., Toronto, Canada). Compound 9 was considered
deprotonated while all the others compounds were considered
neutral in all calculations performed, as a consequence of the
estimation of percentage of neutral/ionized forms computed at the
pH of 7.2 (physiological pH value) and 5.5 (parasite vacuole pH)
using the Handerson-Hasselbach equation. The conformational
space of all compounds was sampled through 500 cycles of
Simulated Annealing (CFF91 force field,16  ) 80r) by following
this protocol: the system was heated up to 1000 K over 2000 fs
(time step ) 3.0); the temperature of 1000 K was applied to the
system for 2000 fs (time step ) 3.0) with the aim of surmounting
torsional barriers; successively temperature was linearly reduced
to 300 K in 1000 fs (time step ) 1.0). Resulting structures were
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subjected to energy minimization within Insight 2005 Discover
module (CFF91 force field, conjugate gradient algorithm;  ) 80r)
until the maximum rms derivative was less than 0.001 kcal/Å and
subsequently ranked by their conformational energy and torsional
angles values. In order to properly analyze the electronic properties,
their most stable conformers were subjected to a full geometry
optimization by semiempirical calculations, using the quantum
mechanical method AM1 in the Mopac 6.0 package17 in Ampac/
Mopac module of Insight 2000.1. GNORM value was set to 0.5.
To reach a full geometry optimization the criteria for terminating
all optimizations was increased by a factor of 100, using the
keyword PRECISE. The lowest energy conformer of Plakortin (1)
was superimposed on artemisinin X-ray structure (CSDS code:
QNGHSU) by fitting the 1,2-dioxane ring on the 1,2,4-trioxane
ring.
Acknowledgment. This work is the result of a research
supported by European Community (ANTIMAL project - EU
contract LSHP-CT-2005-018834) and by Regione Campania
(Italy) (Legge Regionale 5/02, Annualita` 2002, “Metaboliti
secondari da organismi marini come composti guida per la
progettazione razionale di farmaci ad attivita` antifungina ed
antiprotozoaria”). D.T. also acknowledges financial support from
the Italian MIUR, PRIN 2003-062554004. Mass and NMR
spectra were recorded at the “Centro di Servizio Interdiparti-
mentale di Analisi Strumentale”, Universita` di Napoli “Federico
II”. The assistance of the staff is acknowledged.
Supporting Information Available: 1H NMR spectra for
compounds 5-12, Figure S1, and purity criteria for target com-
pounds. This material is available free of charge via the Internet at
http://pubs.acs.org.
References
(1) Snow, R. W.; Guerra, C. A.; Noor, A. M.; Myint, H. Y.; Hay, S. I.
The global distribution of clinical episodes of Plasmodium falciparum
malaria. Nature 2005, 434, 214-217.
(2) White, N. J. Antimalarial drug resistance. J. Clin. InVest. 2004, 113,
1084-1092.
(3) Martensson, A.; Stroemberg, J.; Sisowath, C.; Msellem, M. I.; Gil,
J. P.; Montgomery, S. M.; Olliaro, P.; Ali, A. S.; Bjoerkman, A.
Efficacy of artesunate plus amodiaquine versus that of artemether-
lumefantrine for the treatment of uncomplicated childhood Plasmo-
dium falciparum malaria in Zanzibar, Tanzania. Clin. Infect. Dis.
2005, 41 (8), 1079-1086.
(4) (a) White, N. J. Antimalarial drug resistance and combination chemo-
therapy. Phil. Trans. R. Soc. Lond. B, 1999, 354, 739-749. (b) South
East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) Group,
Lancet 2005, 366, 717. (c) Longo, M.; Zanoncelli, S.; Manera, D.;
Brughera, M.; Colombo, P.; Lansen, J.; Mazue´, G.; Gomes, M.;
Taylor, W. R. J.; Olliaro, P. Effects of the antimalarial drug
dihydroartemisinin (DHA) on rat embryos in vitro. Reprod. Toxicol.
2006, 21, 83-93. (d) Taylor, W. R. J.; White, N. J. Antimalarial
drug toxicity: a review. Drug Safety 2004, 27, 25-61.
(5) Ridley, R. G. Medical need, scientific opportunity and the drive for
antimalarial drugs. Nature 2002, 415, 686-693.
(6) Cafieri, F.; Fattorusso, E.; Taglialatela-Scafati, O.; Ianaro, A.
Metabolites from the sponge Plakortis simplex. Determination of
absolute stereochemistry of plakortin. Isolation and stereostructure
of three plakortin related compounds. Tetrahedron 1999, 55, 7045-
7056.
(7) Fattorusso, E.; Parapini, S.; Campagnuolo, C.; Basilico, N.; Taglialatela-
Scafati, O.; Taramelli, D. Activity against Plasmodium falciparum
of cycloperoxide compounds obtained from the sponge Plakortis
simplex. J. Antimicrob. Chemother. 2002, 50, 883-888.
(8) Campagnuolo, C.; Fattorusso, E.; Romano, A.; Taglialatela-Scafati,
O.; Basilico, N.; Parapini, S.; Taramelli, D. Antimalarial polyketide
cycloperoxides from the marine sponge Plakortis simplex. Eur. J.
Org. Chem. 2005, 5077-5083.
(9) Barluenga, J.; Vazquez-Villa, H.; Ballesteros, A.; Gonzalez, J. M.
Copper(II) Tetrafluoroborate Catalyzed Ring-Opening Reaction of
Epoxides with Alcohols at Room Temperature. Org. Lett. 2002, 4,
2817-2819.
(10) Ohtani, I.; Kusumi, T., Kashman, Y.; Kakisawa, H. High-field FT
NMR application of Mosher’s method. The absolute configurations
of marine terpenoids. J. Am. Chem. Soc. 1991, 113, 4092-4096.
(11) Hu, J.-F.; Gao, H.-F.; Kelly, M.; Hamann, M. T. Plakortides K.-N,
four new cyclic peroxides from an undescribed Jamaican sponge
Plakortis sp. (Homosclerophorida, Plakinidae). Tetrahedron 2001,
57, 9379-9383.
(12) (a) Freeman, F.; Lee, C.; Hehre, W. J.; Po, H. N. Ab initio molecular
orbital calculations of 3,4-dihydro-1,2-dioxin, 3,6-dihydro-1,2-dioxin,
4H-1,3-dioxin (1,3-diox-4-ene), and 2,3-dihydro-1,4-dioxin (1,4-
dioxene). J. Comput. Chem. 1997, 18, 1392-1406. (b) Senthilkumar,
K.; Kolandaivel, P. Structure, conformation and NMR studies on 1,2
dioxane and halogen substituted 1,2-dioxane molecules. Comput. Biol.
Chem. 2003, 27, 173-183.
(13) Trager, W.; Jensen, J. B. Human malaria parasite in continuous
culture. Science 1976, 193, 673-675.
(14) Makler, M. T.; Ries, J. M.; Williams, J. A.; Bancroft, J. E.; Piper,
R. C.; Gibbins, B. L.; Hinrichs, D. J. Parasite lactate dehydrogenase
as an assay for Plasmodium falciparum drug sensitivity. Am. J. Trop.
Med. Hyg. 1993, 48, 739-741.
(15) Parapini, S.; Basilico, N.; Mondani, M.; Olliaro, P.; Taramelli, D.;
Monti, D. Evidence that haem iron in the malaria parasite is not
needed for the antimalarial effects of artemisinin. FEBS Lett. 2004,
575, 91-94.
(16) Maple, J. R.; Hwang, M. J.; Stockfisch, T. P.; Dinur, U; Waldman,
M.; Ewig, C. S.; Hagler, A. T.; Derivation of Class II force fields. I.
Methodology and quantum force field for the alkyl function group
and alkane molecules. J. Comput. Chem. 1994, 15, 162-182.
(17) Stewart, J. J. P. MOPAC: a semiempirical molecular orbital program.
J. Comput.-Aided Mol. Des. 1990, 4, 1-105.
JM060899G
7094 Journal of Medicinal Chemistry, 2006, Vol. 49, No. 24 Fattorusso et al.
